Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
MSD R&D (China) Co., Ltd.
Massachusetts General Hospital
ADC Therapeutics S.A.
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of Pennsylvania
Eli Lilly and Company
Eli Lilly and Company
Autolus Limited
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Institute of Hematology & Blood Diseases Hospital, China
Second Affiliated Hospital, School of Medicine, Zhejiang University
Baylor College of Medicine
Excyte Biopharma Ltd
Celgene
Gilead Sciences
Regeneron Pharmaceuticals
Peking University
Dana-Farber Cancer Institute
The Second Affiliated Hospital of Fujian Medical University
University of Utah
National Institutes of Health Clinical Center (CC)
Ruijin Hospital
Medical College of Wisconsin
Umoja Biopharma
Affiliated Hospital of Jiangsu University
University of Colorado, Denver
University Hospital, Basel, Switzerland
Sanofi
Thomas Helleday Foundation
Verismo Therapeutics
British Columbia Cancer Agency
University of Pennsylvania
Fate Therapeutics
UNC Lineberger Comprehensive Cancer Center
University of Utah
Shanghai Junshi Bioscience Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University
PeproMene Bio, Inc.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Tongji Hospital
M.D. Anderson Cancer Center